Title: Maeil Business-- LegoChem will "have a lot of contracts next year."

Publication: Money Today/ Chan Ok Shin

Date: 1 June 2016

Summary

• CEO Yong Zu Kim, who worked in LG Chemistry for 23 years before founding LegoChem, said his three management points are effectiveness, idea, and talent.

• CEO Yong Zu Kim said, "This year we will try to reach our full potentials."

• Hana Financial Investment Co. acclaimed LegoChem and said, "LegoChem will be recognized for its possibility to be the leader in the global technology field in the second half of this year. We analyze that the current investors has yet to capture the real value of LegoChem's ADC platform. When it receives approval from global corporations and the clinical safety is confirmed, their real value will be reflected on the market."

To view the full article (in Korean), click here ▶

About LegoChem Biosciences

LegoChem Biosciences, Inc. (LCB) is a research-based biotechnology company dedicated to discovering, developing, and commercializing innovative medicines by leveraging our chemistry expertise to make conventional biologics targeted and more potent for the benefit of patients with diseases of high unmet medical needs. We are advancing sustainable pipelines in therapeutic areas in antibiotics, anti-coagulants, oncology, antibody-drug conjugate (ADC), and protein-drug conjugate (PDC).